Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
SAN DIEGO–(BUSINESS WIRE)—- $GOSS–Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated […]
